Lapatinib Completed Phase 2 Trials for Recurrent Endometrial Carcinoma Treatment

IndicationsStatusPurposePhase
CompletedTreatment2
clinicaltrials.gov IdentifierTitleDrugs
NCT00096447Lapatinib in Treating Patients With Recurrent or Persistent Endometrial Cancer